No Priors Ep. 140 | With Benchling Co-Founder and CEO Sajith Wickramasekara | No Priors: AI, Machine Learning, Tech, & Startups

In this episode of No Priors, Sarah Guo interviews Sajith Wickramasekara, the co-founder and CEO of Benchling, a software company focused on biotech R&D. Sajith discusses Benchling's role in modernizing scientific processes, from molecule design to data analysis, and its impact on the biotech and pharmaceutical industries. The conversation explores the current macro environment in biotech, including the rise of Chinese biotech companies and the challenges faced by Western firms. They delve into the potential of AI in accelerating drug discovery, the importance of data-driven decision-making, and Benchling's AI initiatives, including AI agents for automating scientific tasks. Sajith also shares insights on company building, the integration of science and software cultures, and the future of AI in transforming the biotech landscape.

Outlines

Sign in to continue reading, translating and more.

Continue

No Priors Ep. 140 | With Benchling Co-Founder and CEO Sajith Wickramasekara

No Priors: AI, Machine Learning, Tech, & Startups

Introduction to Benchling and the State of Biotech

Factors Influencing the Biotech Macro Cycle

The Impact of Chinese Biotech and the High Cost of Drug Development

The Artisanal Nature of Biotech and the Opportunity with AI

Benchling AI: Simulation Tools and AI Agents

The Role of Scientists in the Age of AI and Trust in AI Outputs

Overcoming Concerns and the Current State of AI Adoption in Pharma

Predictive Models and Business Models in Biotech

Data Transactions and the Value of Tools in Pharma

AI for Drug Discovery and Partnership with Anthropic

Company Building and Hard Decisions

Lessons for Entrepreneurs and Focusing the Team

Integrating Scientists into a Software Company

Interviewing for Orientation and Cultural Exchange

The Importance of Intelligence and AI in Quality-Sensitive Fields

Closing Remarks

No Priors Ep. 140 | With Benchling Co-Founder and CEO Sajith Wickramasekara

No Priors: AI, Machine Learning, Tech, & Startups

00:05Introduction to Benchling and the State of Biotech

Introduction to Benchling and the State of Biotech

04:05Factors Influencing the Biotech Macro Cycle

Factors Influencing the Biotech Macro Cycle

07:30The Impact of Chinese Biotech and the High Cost of Drug Development

The Impact of Chinese Biotech and the High Cost of Drug Development

11:25The Artisanal Nature of Biotech and the Opportunity with AI

The Artisanal Nature of Biotech and the Opportunity with AI

15:56Benchling AI: Simulation Tools and AI Agents

Benchling AI: Simulation Tools and AI Agents

18:36The Role of Scientists in the Age of AI and Trust in AI Outputs

The Role of Scientists in the Age of AI and Trust in AI Outputs

22:21Overcoming Concerns and the Current State of AI Adoption in Pharma

Overcoming Concerns and the Current State of AI Adoption in Pharma

25:33Predictive Models and Business Models in Biotech

Predictive Models and Business Models in Biotech

29:21Data Transactions and the Value of Tools in Pharma

Data Transactions and the Value of Tools in Pharma

32:38AI for Drug Discovery and Partnership with Anthropic

AI for Drug Discovery and Partnership with Anthropic

34:53Company Building and Hard Decisions

Company Building and Hard Decisions

37:01Lessons for Entrepreneurs and Focusing the Team

Lessons for Entrepreneurs and Focusing the Team

40:16Integrating Scientists into a Software Company

Integrating Scientists into a Software Company

42:27Interviewing for Orientation and Cultural Exchange

Interviewing for Orientation and Cultural Exchange

45:26The Importance of Intelligence and AI in Quality-Sensitive Fields

The Importance of Intelligence and AI in Quality-Sensitive Fields

47:51Closing Remarks

Closing Remarks